Cambridge Cancer Genomics

Acquired

CCG.ai empowers clinicians to make personalised treatment strategies…

Cambridge, United Kingdom · Founded 2015 · $4.5M raised

Headquarters
Cambridge
Employees
11–50
Founded
2015
Website
ccg.ai
Total Funding
$4.5M
Last Round
$4.5M Series ADec 2018
Rounds
1
Acquisition Date
Jun 2021

Totals include recorded grants and other qualifying funding, not just equity. What counts toward funding.

Indexed holds 2 funding rounds and 3 investors for this company. The full record is or through the API.

About

CCG.ai exist to ensure that each patient has the right drug, at the right time, to beat their cancer. ‍ We build the software to enable data-driven precision oncology and systematically develop data-driven biomarkers indicative of treatment response. We believe that increasing amounts of clinical and genomic data have the potential to transform cancer treatment, and enable oncologists to make smarter decisions about which drug to use in which circumstance. We are expanding our team in Cambridge, UK, offering a fantastic opportunity for dedicated individuals who are comfortable in a high-work high-reward environment, and who are enthusiastic for a dynamic and varied role. We are looking for people who fit well into our team and company culture, and who like to overcome challenges and drive the business forward. In exchange, we offer a competitive salary with performance related bonuses and stock options, alongside excellent career development opportunities in a fast-growing start-up with a chance to truly impact how cancer is treated. To apply, please send your CV to info@ccg.ai

Summary

Cambridge Cancer Genomics is a Genomics company based in Cambridge, United Kingdom, founded in 2015. It has raised $4.5M in total across 1 round, most recently a $4.5M Series A round in Dec 2018. Investors include Refactor Capital, Romulus Capital and AME Cloud Ventures.

Funding & Exit History

AcquisitionAcquisition by Dante LabsJun 2021

Sign up to see all 2 events

Funding: Series A. Amounts, valuations, and investors where available.

Investors

Similar Companies

BeiGeneIPO

BeOne Medicines develops transformative oncology medicines through rigorous science, an accelerat...

Cambridge, United States10001+Biotech, Oncology
Corporate RoundTotal funding$2.8BJan 2020
GRAILIPO

Biotechnology company developing multi-cancer early detection blood tests using high-intensity ge...

Menlo Park, United States1001–5000Biotech, Genomics
Corporate RoundTotal funding$2.1BJun 2026
Caris Life SciencesIPO

Provides comprehensive molecular profiling and AI-driven precision oncology services for physicia...

Irving, United States1001–5000Diagnostics, Genomics
Growth EquityTotal funding$1.5BApr 2025
Foundation MedicineAcquired

Provides genomic profiling tests and data services to oncologists and biopharma partners to guide...

Cambridge, United States1001–5000Diagnostics, Genomics
Corporate RoundTotal funding$1.1BJan 2015
Ultima Genomics

Ultima Genomics develops high-throughput DNA sequencing platforms that use open-wafer technology ...

Fremont, United States201–500Artificial Intelligence, Healthcare
Series ETotal funding$1.1BJun 2022
Alnylam PharmaceuticalsIPO

Biopharmaceutical company developing and commercializing RNAi therapeutics to treat genetically d...

Cambridge, United States1001–5000Biotech, Genomics
Corporate RoundTotal funding$1.0BApr 2020

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Cambridge Cancer Genomics on Indexed.vc
<a href="https://indexed.vc/companies/ccgenomics"><img src="https://indexed.vc/api/badge/company/ccgenomics" alt="Cambridge Cancer Genomics on Indexed.vc" width="260" height="76" /></a>